AstraZeneca has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said.
https://www.pharmalive.com/wp-content/uploads/2022/03/AstraZenecas-Imfinzi-fails-main-goal-in-advanced-cervical-cancer-study-Reuters-3-24-22.jpg6281200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-05-16 09:12:162023-05-16 10:51:53AstraZeneca to leave leading U.S. drug lobby group